Despite an ever-growing prevalence and increasing economic burden of Alzheimer's
disease (AD) and Parkinson's disease (PD), recent advances in drug development have …

Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors are
commonly used treatments for patients with type 2 diabetes mellitus (T2DM). Both anti …

Aging is an important risk factor for cardiovascular diseases, and aging‐related cardiac
dysfunction serves as a major determinant of morbidity and mortality in elderly populations …

Background Glucagon-like peptide-1 receptor agonists (GLP-1RA) and bariatric surgery
have proven to be effective treatments for obesity and cardiometabolic conditions. We aimed …

Obesity-related heart failure with preserved ejection fraction (HFpEF) has become a well-
recognized HFpEF subphenotype. Targeting the unfavorable cardiometabolic profile may …

Aim The cardiovascular benefits provided by glucagon‐like peptide‐1 receptor agonists
(GLP‐1RAs) extend beyond weight reduction and glycaemic control. One possible …

Sepsis causes high mortality in the setting of septic shock. LEADER and other trials revealed
cardioprotective and anti-inflammatory properties of glucagon-like peptide-1 (GLP-1) …

An increased risk of lower limb amputations (LLA) has been suspected with the use of
sodium-glucose cotransporter type 2 inhibitors (SGLT2is) after the publication of CANVAS …

Type 2 diabetes is associated with a higher risk of cardiac arrhythmias, especially in
presence of cardiovascular disease and/or heart failure. Even if atrial fibrillation/flutter …

Background: Several clinical trials have demonstrated that glucagon-like peptide-1 (GLP-1)
receptor agonists (GLP-1RAs) reduce the incidence of non-fatal myocardial infarction (MI) in …